Editas Medicine (NASDAQ:EDIT – Get Free Report) and Onconetix (NASDAQ:ONCO – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, earnings, institutional ownership, risk and valuation.
Insider & Institutional Ownership
71.9% of Editas Medicine shares are owned by institutional investors. Comparatively, 23.9% of Onconetix shares are owned by institutional investors. 3.1% of Editas Medicine shares are owned by company insiders. Comparatively, 0.3% of Onconetix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Analyst Recommendations
This is a summary of current ratings and price targets for Editas Medicine and Onconetix, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Editas Medicine | 1 | 0 | 5 | 0 | 2.67 |
| Onconetix | 1 | 0 | 0 | 0 | 1.00 |
Valuation and Earnings
This table compares Editas Medicine and Onconetix”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Editas Medicine | $40.52 million | 9.91 | -$160.06 million | ($0.75) | -3.49 |
| Onconetix | $810,000.00 | 3.97 | -$14.03 million | $248.12 | 0.00 |
Onconetix has lower revenue, but higher earnings than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Editas Medicine and Onconetix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Editas Medicine | -157.32% | -196.63% | -38.17% |
| Onconetix | -1,575.89% | -91.95% | -53.76% |
Risk & Volatility
Editas Medicine has a beta of 2, meaning that its stock price is 100% more volatile than the S&P 500. Comparatively, Onconetix has a beta of 2.61, meaning that its stock price is 161% more volatile than the S&P 500.
Summary
Editas Medicine beats Onconetix on 9 of the 14 factors compared between the two stocks.
About Editas Medicine
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
About Onconetix
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
